about
VEGF links hippocampal activity with neurogenesis, learning and memoryKnockdown and overexpression of NR1 modulates NMDA receptor function.Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.Long-term follow-up after gene therapy for canavan disease.Somatic gene transfer of cAMP response element-binding protein attenuates memory impairment in aging ratsAAV-mediated overexpression of neuroserpin in the hippocampus decreases PSD-95 expression but does not affect hippocampal-dependent learning and memory.Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion sizeTranscriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transferGene regulation systems for gene therapy applications in the central nervous system.A novel bicistronic sensor vector for detecting caspase-3 activation.An Immunological Approach to Increase the Brain's Resilience to Insults.Phosphorylation-dependent degradation of transgenic CREB protein initiated by heterodimerization.Inhibition of NMDA receptor function with an anti-GluN1-S2 antibody impairs human platelet function and thrombosis.Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington's Disease.Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels.Differential expression of inducible transcription factors in basal ganglia neurons.Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes.A novel role of circadian transcription factor DBP in hippocampal plasticity.Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia.Blood-brain glucose transfer in the mouse.CCAAT-enhancer binding protein alpha is expressed in activated microglial cells after brain injury.Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.Blood-brain barrier penetration of felbamate.Differential regulation by MK801 of immediate-early genes, brain-derived neurotrophic factor and trk receptor mRNA induced by a kindling after-discharge.Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus.Trk receptor alterations in Alzheimer's disease.Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogeneticsInduction of clusterin in the immature brain following a hypoxic-ischemic injuryClusterin accumulates in dying neurons following status epilepticusNeuronal injury following electrically induced status epilepticus with and without adenosine receptor antagonismc-Jun promotes neurite outgrowth and survival in PC12 cellsAn oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsyNeuronal death and survival in two models of hypoxic-ischemic brain damage
P50
Q28578381-026F2758-D61D-4BD7-B28A-A79153690C14Q30451702-B8598830-5161-4AF0-A810-3A1B90217D09Q33713108-653E277D-F94D-4A25-840E-B7C8758F2AC0Q34318553-5EF2C3CA-C57E-462D-9798-45E4D97FAB03Q34448297-FC42A8F7-C728-4EAF-9CEC-595C0BD1FFCEQ35114530-FF8CC98B-AF8C-4B91-B67B-F0F559C419A6Q37301326-1C13EBED-3E9C-4590-82E6-72F9EE9D3AFCQ37458119-1DF37D99-DB0B-4478-9D3D-904314AA887EQ37978318-0035E601-F9E3-4B09-93B1-5CEC4A3FA7A1Q38931552-D047FFD6-E420-496F-A391-950F02DE3B2EQ39266351-20F23EBB-0762-4492-82CD-D9E1036AE2B7Q40196444-FE4BA3CF-3889-499C-9450-B319C4651BCBQ40300422-7823C16B-5DBE-4B90-996E-FFFA6EEFD9B1Q41093242-9AA0A88D-C481-448D-A859-7E14171C056AQ42247303-AE1C2E8B-D61E-470F-8F5B-A7429AFC5CE5Q42521425-166488A6-2EB8-458D-9867-460032A12CCCQ44719583-AD687706-7844-4689-BCCA-5C484ABC020FQ45735544-152D1A35-2DF6-434A-B626-87A9A53DE274Q46780685-B07EE769-D145-480C-B9C3-4DF06FFB6A4FQ48150837-DB708172-8E72-468C-9C39-553A2CB19DD2Q48291667-08901983-B2B2-4DF3-8075-A7E40ABBD7CAQ48364089-428A224D-FBB8-472A-AB04-2334ABDBA332Q48375085-122AE304-AD9E-4AF0-8995-FA016ACCAE74Q48438674-1B48144F-FE73-4B0A-894E-7C4AFF7DCD72Q48487618-6B9E6810-D088-4B53-A89F-F282FDA6AB53Q48565827-116F2C81-CF29-4582-9A04-B9AC492301F8Q48568041-62F49CEC-FBA0-4665-A44A-17C8D076277FQ48766874-07DCD959-217D-452C-8041-C32F75CFA822Q48880171-04D526C1-7279-48D0-A8A9-C1A99959531BQ52405821-F3F5A525-DF66-4EBD-85DA-A794752E0819Q64106645-5A2B52FE-11E3-476A-AF57-6D1E555EDDE3Q71525724-C3D7C69B-EB5D-434B-9793-0A152EB56B8DQ71589623-92BC5039-8F55-45C1-B171-AF222ED01BE1Q71994516-DBD72431-28E2-471D-ADD7-30D760F73CE0Q73173837-1CB2926C-277F-4D2A-B6F5-087BF35BC051Q73479417-739D792A-FF9A-4A25-9E22-5152E3A796CEQ77343222-F73B3359-5725-4412-BF4D-FE5EEF9D01B0
P50
description
researcher
@en
հետազոտող
@hy
name
D Young
@ast
D Young
@en
D Young
@es
D Young
@nl
D Young
@sl
type
label
D Young
@ast
D Young
@en
D Young
@es
D Young
@nl
D Young
@sl
altLabel
Deborah Young
@en
prefLabel
D Young
@ast
D Young
@en
D Young
@es
D Young
@nl
D Young
@sl
P106
P1153
25935582800
P31
P496
0000-0003-1085-2824